Hester Biosciences' Q1 FY 2026-27 Quarterly Results

Result Summary

• Hester Biosciences Ltd reported a 18.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a decline of 8.7%.
• Its expenses for the quarter were down by 15.9% QoQ and 4.0% YoY.
• The net profit increased 484.8% QoQ and increased 459.5% YoY.
• The earnings per share (EPS) of Hester Biosciences Ltd stood at 113.71 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Hester Biosciences Ltd. is a prominent player in the pharmaceutical industry, primarily engaged in the production and distribution of vaccines and animal healthcare products. Known for its expertise in veterinary biologicals, the company provides a range of vaccines for poultry and large animals, along with other health products. Hester Biosciences has been an integral part of the animal healthcare sector in India and has also expanded its reach internationally. As of the latest updates up to October 2023, the company has been focused on expanding its product portfolio and enhancing its manufacturing capabilities. However, specific recent developments concerning the company are not available in the provided data.

Revenue

The revenue section highlights the company's total income over the recent quarters. For Q1FY27, Hester Biosciences reported a total income of ₹78.89 crores, which marks a decline from the preceding quarter Q4FY26, where the total income was ₹97.08 crores, resulting in a quarter-over-quarter decrease of 18.7%. Comparing year-over-year performance, the total income also decreased by 8.7% from Q1FY26, where the total income was ₹86.42 crores. These figures indicate the company's revenue trends over the past fiscal year, with a notable reduction both from the previous quarter and the same quarter of the previous year.

Profitability

In terms of profitability, Hester Biosciences showed significant fluctuations. The profit before tax in Q1FY27 was ₹99.64 crores, which reflects a substantial increase of 328.9% from Q4FY26, where it stood at ₹23.23 crores. Year-over-year, the profit before tax increased by 420.6% from ₹19.14 crores in Q1FY26. The profit after tax for Q1FY27 was ₹96.73 crores, marking a sharp rise of 484.8% from the previous quarter's ₹16.54 crores and a 459.5% increase from ₹17.29 crores in the same quarter of the previous year. Earnings per share also reflected this trend, with Q1FY27 at ₹113.71 compared to ₹19.45 in Q4FY26 and ₹20.33 in Q1FY26, showing similar percentage increases as the profit after tax.

Operating Metrics

Examining the operating metrics, total expenses for Q1FY27 were reported at ₹64.59 crores, which is a decline from ₹76.79 crores in Q4FY26, showing a quarter-over-quarter decrease of 15.9%. Year-over-year, there was a 4.0% decrease from ₹67.28 crores in Q1FY26. The tax expense also decreased to ₹4.95 crores in Q1FY27 from ₹8.54 crores in Q4FY26, showing a reduction of 42.0%, though tax expenses increased by 71.3% compared to ₹2.89 crores in Q1FY26. These metrics provide insight into the company's cost management and tax obligations over the periods analyzed.